A Study of CBP-1018 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug
conjugate CBP-1018 in patients with advanced solid tumors. This study will be conducted in 2
parts: Part A (Dose Escalation) and Part B (Dose Expansion). Both parts include screening
period, treatment period, end of treatment (EOT)/withdrawal, safety follow-up (SFU) and
long-term-follow-up (LTFU). CBP-1018 will be administrated on eligible subjects until disease
progression, unacceptable toxicity, withdrawal of consent or Sponsor's decision to stop the
study, etc.